Literature DB >> 19707953

Extended pelvic lymphadenectomy for prostate cancer: will the previously reported benefits be reproduced in hospitals with lower surgical volumes?

Christian Lindberg1, Thomas Davidsson, Sigurdur Gudjónsson, Rafn Hilmarsson, Fredrik Liedberg, Ola Bratt.   

Abstract

OBJECTIVE: In the European Association of Urology guidelines on prostate cancer an extended pelvic lymphadenectomy (ePLND) is now recommended, instead of a dissection limited to the obturator fossae (lPLND). This recommendation relies on studies reporting that metastatic disease is identified twice as often with ePLND as with lPLND, with only moderately increased complications. However, these studies were from high-volume centres. This study investigated whether these results could be repeated in a hospital with lower surgical volume, more typical for the Nordic countries.
MATERIAL AND METHODS: From January 2002 to September 2007 172 patients underwent radical prostatectomy and PLND at the University Hospital of Lund, 108 with ePLND and 64 with lPLND. Perioperative complications and the number of lymph-node metastases found were registered.
RESULTS: A median of 17 lymph nodes was identified with ePLND compared with seven with lPLND. Metastases were identified in four out of 64 patients in the lPLND group (6%), versus 22 out of 108 in the ePLND group (20%). In the ePLND group 10 of the patients with metastases had such exclusively outside the obturator fossae. Complications were significantly more common after ePLND (p=0.007): lymphoceles (18 vs 9%), pulmonary embolism (4.6 vs 1.6%), deep venous thrombosis (1 vs 1.5%) and other (haematomas and infectious including sepsis (8 vs 0%).
CONCLUSIONS: Almost half of the patients with metastases are misclassified by lPLND. Complications are significantly more common after ePLND. This implies that ePLND should be performed, but in selected patients and by high-volume surgeons only.

Entities:  

Mesh:

Year:  2009        PMID: 19707953     DOI: 10.3109/00365590903200524

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

Review 1.  A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma.

Authors:  Liang Gao; Lu Yang; Xiao Lv; Siyuan Bu; Fan Wan; Shengqiang Qian; Qiang Wei; Ping Han; Tianyong Fan
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-27       Impact factor: 4.553

Review 2.  Comparison of perioperative complications for extended vs standard pelvic lymph node dissection in patients undergoing radical prostatectomy for prostate cancer: a meta-analysis.

Authors:  Jerry Kong; Benjamin Lichtbroun; Joshua Sterling; Yaqun Wang; Qingyang Wang; Eric A Singer; Thomas L Jang; Saum Ghodoussipour; Isaac Yi Kim
Journal:  Am J Clin Exp Urol       Date:  2022-04-15

3.  Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer.

Authors:  Anthony Van Baelen; Nicolas Mottet; Martin Spahn; Alberto Briganti; Paolo Gontero; Steven Joniau
Journal:  Adv Urol       Date:  2011-10-09

4.  Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection.

Authors:  Lisa Moris; Thomas Van den Broeck; Lorenzo Tosco; Anthony Van Baelen; Paolo Gontero; Robert Jeffrey Karnes; Wouter Everaerts; Maarten Albersen; Patrick J Bastian; Piotr Chlosta; Frank Claessens; Felix K Chun; Markus Graefen; Christian Gratzke; Burkhard Kneitz; Giansilvio Marchioro; Rafael Sanchez Salas; Bertrand Tombal; Henk Van Der Poel; Jochen Christoph Walz; Gert De Meerleer; Alberto Bossi; Karin Haustermans; Francesco Montorsi; Hendrik Van Poppel; Martin Spahn; Alberto Briganti; Steven Joniau
Journal:  Front Surg       Date:  2016-12-16

5.  Optimizing the management of high-risk, localized prostate cancer.

Authors:  Debasish Sundi; Byong Chang Jeong; Seung Bae Lee; Misop Han
Journal:  Korean J Urol       Date:  2012-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.